Toward the realization of next-generation healthcare, the utilization of large-scale data on genome information and medical/health information is rapidly advancing in Japan and abroad, and whole genome information is already a powerful approach in drug discovery. In fact, human genetics has been shown to increase the probability of success in drug development, with the probability of approval for drugs with a human genetic background among those developed up to Phase I clinical trials being about four times higher. the probability of success is said to be even higher when Missense and Deleterious mutations are present. Particularly impressive is the report that two-thirds of new drugs approved by the U.S. FDA in 2021 were based on evidence from human genetics. In other words, a key issue in drug discovery is how to shorten development time and increase the probability of success by utilizing genomic information.

Under these circumstances, Genomics England has formed the Discovery Forum in the U.K., in which more than 120 companies, including Japanese companies involved in pharmaceuticals, clinical testing, and bioinformatics, have joined to start drug discovery and next-generation healthcare development utilizing genome information and medical information. In Japan, pharmaceutical companies are also involved in this project. In Japan, there has been a growing demand for the expansion of the Japanese genome information infrastructure, especially among pharmaceutical companies, and Tohoku University Tohoku Medical Megabank Organization, in cooperation with the Ministry of Education, Culture, Sports, Science and Technology and the "Consortium for Integrated Analysis of Whole Genome Information and Medical and Health Information" formed by the organization and five pharmaceutical companies, has started a project to develop a genome analysis system for 100,000 general residents who are participating in a prospective cohort. The CBI is promoting innovative drug development through integrated analysis of whole genome information and medical/health information of 100,000 general population.

We are now pleased to invite researchers and experts in the fields of informatics, computational chemistry, drug discovery chemistry, biology, and medicine, who are active in the development of next-generation health care by utilizing large-scale data, to speak at the 2023 CBI Society Conference. Together, we will discuss strategies on how to form the foundation of genome information, medical and health information, and how to utilize data science and AI to realize new medicine and drug discovery against the backdrop of DX accelerated by Wiz Post Corona. We hope this will be an opportunity to share the latest research and discuss the direction we should take in the future.

We look forward to the active participation of not only those involved in medicine and drug discovery, but also those from industry and academia who are involved in a wide range of health and lifestyle-related fields, as well as those who are actually working to realize next-generation healthcare by utilizing large-scale data, and those who are interested in getting started. We look forward to your active participation.

CBI Society 2023 Annual Meeting

    Masayuki Yamamoto (Tohoku Medical Megabank Organization, Tohoku University )
Organizing Committee Chair
    Soichi Ogishima (INGEM/Tohoku Medical Megabank Organization, Tohoku University)